Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 827 in Moderate to Severe Crohn's Disease
2010-019544-39Phase 2Terminated
- Sponsor
- Amgen
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing AMG 827 with Placebo (2 arms). Primary endpoint: Clinical remission at week 6. Started Aug 2010; status: terminated.
02
Drugs
brodalumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2010-019544-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019544-39.